Skip to main content

Table 1 Demographic and clinical characteristics of the whole sample and ATN groups

From: Automatized FACEmemory® scoring is related to Alzheimer’s disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort

 

Whole sample

ATN groups

Normal

AD

SNAP

N

94

24

15

43

Sex n (%) men

37 (39.36)

11 (45.80)

5 (33.30)

18 (41.90)

Age in years (mean/SD)

60.74 (3.42)

59.83 (2.55)

59.83 (2.55)

60.30 (4.17)

Schooling years (mean/SD)

12.05 (5.08)

12.42 (5.49)

12.42 (5.49)

11.86 (4.39)

MMSE (mean/SD)

28.00 (1.50)

28.13 (1.57)

27.80 (1.61)

28.00 (1.50)

MCI type n (%) aMCI

46 (48.94)

7 (29.16)

9 (60.00)

21 (48.84)

  1. ATN groups: (1) Normal: normal AD biomarkers (A-T-N-); (2) AD: Alzheimer’s disease continuum (including A+T-N-, A+T+N-, A+T+N+, and A+T-N+); and (3) SNAP: non-AD pathologic changes (including A-T+N-, A-T-N+, and A-T+N+), where A refers to aggregated Aβ, T to aggregated tau, and N to MRI neurodegeneration or neuronal injury
  2. MMSE Mini-Mental State Examination, SD Standard deviation, MCI Mild cognitive impairment, aMCI Amnestic mild cognitive impairment